People Background Check
Find People:

David S Proia, Age 57180 Hunnewell Ave, Newton, MA 02458

Get Report
Known as:
David S Proi Dave S Proia David S Prola David Poia David Stephen
Related to:
Dawn M Proia 51

David Proia Phones & Addresses

180 Hunnewell Ave, Newton, MA 02458

11 Cottage St, Newton, MA 02458

13 Cottage St, Newton, MA 02458

51 Salisbury Rd, Newton, MA 02458

9008 Hernando St, Brooksville, FL 34613

Spring Hill, FL

Waltham, MA

Port Richey, FL

Show more

Social networks

David S Proia

Linkedin

Work

Company: Harmon law offices, p.c. Apr 2012 to Dec 2013 Position: Services supervisor

Education

School / High School: Waltham Senior High 2000

Skills

Social Media • Customer Service • Data Entry • Leadership

Languages

English

Interests

Kids • Collecting Antiques • Electronics • Home Improvement • Reading • Sports • The Arts • Collecting

Industries

Law Practice

Mentions for David S Proia

David Proia resumes & CV records

Resumes

David Proia Photo 17

Salesperson

Location:
161 High St, Waltham, MA 02453
Industry:
Law Practice
Work:
Harmon Law Offices, P.c. Apr 2012 - Dec 2013
Services Supervisor John Brewers Tavern Dec 1998 - Mar 2011
N and A Patsticketcenter Dec 1998 - Mar 2011
Salesperson
Education:
Waltham Senior High 2000
Waltham High School 1997 - 2000
Skills:
Social Media, Customer Service, Data Entry, Leadership
Interests:
Kids
Collecting Antiques
Electronics
Home Improvement
Reading
Sports
The Arts
Collecting
Languages:
English

Publications & IP owners

Us Patents

Cancer Therapy Using A Combination Of A Hsp90 Inhibitory Compounds And A Egfr Inhibitor

US Patent:
2013015, Jun 13, 2013
Filed:
Apr 19, 2011
Appl. No.:
13/642068
Inventors:
Ronald K. Blackman - Brookline MA, US
Kevin Paul Foley - Landsdale PA, US
David Proia - Newton MA, US
Assignee:
Synta Pharmaceuticals Corp. - Lexington MA
International Classification:
A61K 31/517
A61K 31/4196
US Classification:
5142664
Abstract:
A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.

Cancer Therapy Using A Combination Of A Hsp90 Inhibitory Compounds And A Vegf Inhibitor

US Patent:
2013015, Jun 20, 2013
Filed:
Apr 19, 2011
Appl. No.:
13/642064
Inventors:
Ronald K. Blackman - Brookline MA, US
Kevin Paul Foley - Landsdale PA, US
David Proia - Newton MA, US
Assignee:
Synta Pharmaceuticals Corp. - Lexington MA
International Classification:
A61K 39/395
A61K 31/4196
US Classification:
4241331, 514384, 514383
Abstract:
A pharmaceutical combination comprising a VEGF inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical combinations described herein.

Cancer Therapy Using A Combination Of A Hsp90 Inhibitory Compound And A Topoisomerase Ii Inhibitor

US Patent:
2013017, Jul 4, 2013
Filed:
May 23, 2011
Appl. No.:
13/699517
Inventors:
Ronald K. Blackman - Brookline MA, US
Kevin Paul Foley - Landsdale PA, US
David Proia - Newton MA, US
Assignee:
SYNTA PHARMACEUTICALS CORP. - Lexington MA
International Classification:
A61K 31/4196
A61K 31/7048
A61K 39/395
A61K 38/21
A61K 31/704
A61K 31/568
A61K 33/24
A61K 31/69
A61K 31/65
A61K 31/555
A61K 31/664
A61K 38/19
A61K 31/675
A61K 31/439
US Classification:
424 857, 514 93, 514384, 514 27, 514383, 4241331, 424649, 424 851
Abstract:
A pharmaceutical combination comprising a topoisomerase II inhibitor, and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.

Combination Therapy Of Hsp90 Inhibitory Compounds With Proteasome Inhibitors

US Patent:
2013033, Dec 12, 2013
Filed:
Jan 10, 2012
Appl. No.:
13/979017
Inventors:
David Proia - Newton MA, US
Julie Friedland - Burlington MA, US
Assignee:
SYNTA PHARMACEUTICALS CORP. - Lexington MA
International Classification:
A61K 31/4196
A61K 31/69
A61K 31/675
US Classification:
514 64, 514384, 514 80, 514383
Abstract:
A composition comprising a proteasome inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder such as cancer in a subject in need thereof, using pharmaceutical combinations described herein.

Combination Breast Cancer Therapy With Hsp90 Inhibitory Compounds

US Patent:
2014000, Jan 2, 2014
Filed:
Dec 7, 2011
Appl. No.:
13/992591
Inventors:
David Proia - Newton MA, US
Assignee:
SYNTA PHARMACEUTICALS CORP. - Lexington MA
International Classification:
A61K 31/675
A61K 31/4196
A61K 31/138
A61K 31/565
US Classification:
514 80, 514171, 514384
Abstract:
Methods for treating breast cancer, comprising administering to the subject an effective amount of a selective estrogen receptor modulator and an effective amount of a compound represented by the following structural formula: (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.

Hsp90 Inhibitory Compounds In Treating Jak/Stat Signaling-Mediated Cancers

US Patent:
2014004, Feb 13, 2014
Filed:
Feb 24, 2012
Appl. No.:
14/001427
Inventors:
Ronald K. Blackman - Brookline MA, US
Kevin P. Foley - Landsdale PA, US
David Proia - Newton MA, US
Assignee:
SYNTA PHARMACEUTICALS CORP. - Lexington MA
International Classification:
A61K 31/4196
US Classification:
514384, 435375
Abstract:
Methods for treating a subject with cancer mediated through dysregulated, aberrant, or defective JAK/STAT signaling, are provided, comprising determining the level of the JAK/STAT signaling in a sample derived from a subject in need of treatment, wherein the presence of dysregulated, aberrant, or defective JAK/STAT signaling is indicated, administering to the subject an effective amount of a triazolone compound as described herein.

Combination Therapy Of Hsp90 Inhibitory Compounds With Radiotherapy

US Patent:
2014005, Feb 20, 2014
Filed:
Feb 22, 2012
Appl. No.:
14/001039
Inventors:
Kevin P. Foley - Landsdale PA, US
David Proia - Newton MA, US
Assignee:
SYNTA PHARMACEUTICALS CORP. - Lexington MA
International Classification:
A61K 31/675
A61K 45/06
A61K 31/4196
US Classification:
514 80, 514384, 4351731
Abstract:
Methods for treating cancer in a subject, comprising administering to the subject an effective amount of a compound represented by the following structural formula a tautomer, or a pharmaceutically acceptable salt thereof in combination with radiotherapy. The variables depicted in the structural formula are defined herein.

Prostate Cancer Therapy With Hsp90 Inhibitory Compounds

US Patent:
2014005, Feb 20, 2014
Filed:
Feb 23, 2012
Appl. No.:
14/001465
Inventors:
David Proia - Newton MA, US
Suqin He - West Roxbury MA, US
Assignee:
SYNTA PHARMACEUTICALS CORP. - Lexington MA
International Classification:
A61K 31/4196
C07F 9/6518
C07D 403/10
A61K 31/675
A61K 31/337
US Classification:
514 80, 514384
Abstract:
Method for treating a subject with prostate cancer, comprising administering to the an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.

Possible Relatives

Dawn M Proia  Linda M Proia  Louise M Proia  Susan E Proia  August L Proia  Carol A Proia  David J Last  David K Stancil  David J Stancombe  David R Standefer 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.